<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3015">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757818</url>
  </required_header>
  <id_info>
    <org_study_id>CPC COVID</org_study_id>
    <nct_id>NCT04757818</nct_id>
  </id_info>
  <brief_title>Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.</brief_title>
  <acronym>CPC COVID</acronym>
  <official_title>Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentaid SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IrsiCaixa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dentaid SL</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, parallel, randomized, placebo-controlled clinical study. Subjects with a PCR or&#xD;
      rapid antigen test positive for SARS-CoV-2,&#xD;
&#xD;
      symptomatic of 3 or less days of onset of symptoms, or asymptomatic will be included.&#xD;
      Subjects who agree to participate and who are eligible&#xD;
&#xD;
      will be randomized to perform a mouth rinse and gargle with a 0.07% CPC mouthwash&#xD;
      (experimental) or with a substance of the same color (placebo). Saliva samples will be taken&#xD;
      before rinsing and 1 hour and 3 hours after. Saliva samples will be sent to a centralized&#xD;
      laboratory for SARS-CoV-2&#xD;
&#xD;
      viral load determination, rapid antigen testing, viral infectivity testing, and storage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CPC is a monocationic molecule in nature, with a substantivity of 3 to 5 hours, soluble in&#xD;
      alcohol and in aqueous solutions, and can act as a&#xD;
&#xD;
      detergent and antiseptic. It is neither corrosive nor oxidizing and has a neutral pH. It has&#xD;
      viricidal activity, since its mechanism of action is linked&#xD;
&#xD;
      to the alteration of the lipid envelope, allowing the degradation of the lipid bilayer in&#xD;
      enveloped viruses -such as respiratory syncytial virus&#xD;
&#xD;
      and coronaviruses-, through physicochemical interactions, causing the breakdown and&#xD;
      inactivation of the virus. Substantial viricidal activity&#xD;
&#xD;
      is observed even at very low concentrations of CPC without development of resistance.&#xD;
      Furthermore, the CPC in the formulation reduces&#xD;
&#xD;
      the mortality and morbidity associated with the influenza virus in vivo.&#xD;
&#xD;
      In 2015 the Scientific Committee on Consumer Safety (SCSS) of the European Union (SCCS /&#xD;
      1548/15) reviewed the CPC's toxicity, local&#xD;
&#xD;
      toxicology and safety data, with safety conclusions for concentrations less than 0.1% for its&#xD;
      oral use.&#xD;
&#xD;
      Study procedures will be as follows:&#xD;
&#xD;
      The study activities will take place in 1 day (total interval of 3 hours from the baseline&#xD;
      sample collection to the last sample collection).&#xD;
&#xD;
      The investigator will obtain the informed consent of subjects with a positive result of PCR&#xD;
      or antigen test for SARS-CoV-2 and will verify that the subject meets all the inclusion&#xD;
      criteria and none of the exclusion criteria. The researcher will assign a correlative kit&#xD;
      number (randomization), instruct the subject in the procedure of self-collection of a saliva&#xD;
      sample and the subject will self-collect the first saliva sample in front of the&#xD;
      investigator, who will be able to correct the errors observed in the self-take.&#xD;
&#xD;
      Hour 0: The subject will rinse and gargle with 15 mL of mouthwash (experimental or placebo)&#xD;
      for 1 minute (30 seconds of rinsing and 30 seconds of gargling). The researcher will indicate&#xD;
      to the subject the hours in which the second and third saliva samples should be taken. The&#xD;
      subject must refrain from brushing their teeth, eating and drinking, except water, and may&#xD;
      return home.&#xD;
&#xD;
      Hour 1: One hour after mouthwash use, the subject will self-collect the second saliva sample.&#xD;
      The subject must refrain from brushing teeth, eating and drinking, except water, until the&#xD;
      third sample is collected at 3 hours.&#xD;
&#xD;
      Hour 3: Three hours after the use of the mouthwash, the subject will self-collect the third&#xD;
      saliva sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">March 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, parallel, placebo-controlled clinical study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>1 hour after intervention</time_frame>
    <description>Viral load of SARS-CoV-2 in saliva 1 hour after use of 0,07% CPC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>3 hours after intervention</time_frame>
    <description>viral load of SARS-CoV-2 in saliva 3 hour after use of 0,07% CPC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>3 hours after intervention</time_frame>
    <description>Viral load of SARS-CoV-2 in saliva 3 hour after use of 0,07% CPC in participants with COVID-19 symptomatology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Vitro Infectivity</measure>
    <time_frame>Before and 3 hours after intervention</time_frame>
    <description>In Vitro Infectivity of Viruses Recovered from Saliva of Subjects with Confirmed SARS-CoV-2 Infection Before and After Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of rapid SARS-CoV-2 antigen tests in saliva samples compared to RT-qPCR</measure>
    <time_frame>3 hours after</time_frame>
    <description>To compare the sensitivity and specificity of rapid SARS-CoV-2 antigen tests compared to RT-qPCR in saliva</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>0.07% cetylpyridinium chloride (CPC) in mouthwash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Distilled water with the same colorant as the experimental product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.07% cetylpyridinium chloride (CPC) in mouthwash</intervention_name>
    <description>A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.</description>
    <arm_group_label>0.07% cetylpyridinium chloride (CPC) in mouthwash</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Distilled water with the same colorant as the experimental product</intervention_name>
    <description>A mouthwash and gargles with 15 ml of distilled water for 1 minute</description>
    <arm_group_label>Distilled water with the same colorant as the experimental product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age equal to or greater than 18 years&#xD;
&#xD;
          2. 2. Confirmation of SARS-CoV-2 infection, determined by PCR or validated rapid antigen&#xD;
             test1 from a nasopharyngeal smear performed in ≤3 days.&#xD;
&#xD;
          3. Without symptoms of COVID-19 or with symptoms with ≤3 days of evolution&#xD;
&#xD;
          4. Cognitive and motor ability to perform mouthwashes and gargles&#xD;
&#xD;
          5. Willingness to comply with the requirements of the protocol&#xD;
&#xD;
          6. Understanding of the information provided in relation to the objectives and procedures&#xD;
&#xD;
          7. Provide your consent freely to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of mouthwashes, in the last 24 hours&#xD;
&#xD;
          2. Use of VITIS pastes and / or PERIO AID gel, in the last 24 hours&#xD;
&#xD;
          3. Four or more days of symptoms compatible with COVID-19.&#xD;
&#xD;
          4. Recent medical diagnosis (≤ 1 month) of pneumonia&#xD;
&#xD;
          5. Cognitive impairment or other reason that, in the investigator's discretion,&#xD;
             contraindicates participation in the study&#xD;
&#xD;
          6. Hyposialia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oriol Mitjà Villar, PhD, MD</last_name>
    <phone>'93 465 78 97</phone>
    <email>omitja@flsida.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CAP Gorg</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08913</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Moreno Vicente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Gran Sol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08914</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naiara Mayordomo Vicente</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Esmoris Cerezuela</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP St Roc</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08918</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cristina Coy Vidal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Dr Barraquer</name>
      <address>
        <city>Sant Adrià De Besòs</city>
        <state>Barcelona</state>
        <zip>08930</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cecilia Alonso Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Barri Llatí</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>08921</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaume Sans Acuña</last_name>
    </contact>
    <investigator>
      <last_name>Jaume Sans Acuña</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Fondo</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karmen Harutunian Ayvazian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Santa Rosa</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meritxell Garcia Sánchez-Paniagua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Singuerlin</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>08924</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meritxell Calatayud Mañosa, MD,Phd</last_name>
    </contact>
    <investigator>
      <last_name>Meritxell Calatayud Mañosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Dr Robert</name>
      <address>
        <city>Badalona</city>
        <zip>08911</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Murillo Díez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Cetylpyridinium chloride</keyword>
  <keyword>COVID19</keyword>
  <keyword>Mouthwash</keyword>
  <keyword>Saliva sample</keyword>
  <keyword>RT-qPCR</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetylpyridinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

